Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study. (June 2015)

• Record Type: Journal Article
• Authors: Asadi-Ghalehni, Majid; Ghaemmaghami, Mohamad; Klimka, Alexander; Javanmardi, Masoud; Navari, Mohsen; Rasaee, Mohammad Javad
• Is Part Of: Immunopharmacology and immunotoxicology. Volume 37:Number 3(2015:Jun.)
• Page Start: 274
• Page End: 279
• Publication Date: 2015-06
• Subjects: Immunopharmacology -- Periodicals; Immunotoxicology -- Periodicals; Antibody-toxin conjugates -- Periodicals; Immunology -- Periodicals; 615.37
• DOI: 10.3109/08923973.2015.1027917
• Languages: English
• ISSNs: 0892-3973

Abstract

<abstract> <title>Abstract</title> <p>To date, several small molecule inhibitors and monoclonal-antibodies (like ICR-62) have been used to treat tumors over-expressing epidermal growth factor receptor (EGFR). However, the limitations associated with these conventional applications accentuate the necessity of alternative approaches. Mimotopes as compelling molecular tools could rationally be employed to circumvent these drawbacks. In the present study, an M13 phage displaying ICR-62 binding peptide mimotope is exploited as a vaccine candidate. It exhibited high affinity towards ICR62 and polyclonal anti-P-BSA antibodies. Following the mice immunization, phage-based mimotope vaccine induced humoral immunity. Elicited anti-EGFR mimotope antibodies were detected using ELISA method. Moreover, the phage vaccine was tested on the Lewis lung carcinoma mice model to investigate the prophylactic and therapeutic effects. The tumor volume was measured and recorded in different animal groups to evaluate the anti-tumor effects of the vaccine. Our data indicate that the reported phage-based mimotope could potentially elicit specific antibodies resulting in low titers of EGFR-specific antibodies and reduced tumor growth. However, <italic>in vivo</italic> experiments of prophylactic or therapeutic vaccination showed no specific advantage. Furthermore, phage-mimotope vaccine might be a promising approach in the field of cancer immunotherapy.</p> </abstract>